Acta Scientific Microbiology (ISSN: 2581-3226)

Research Article Volume 4 Issue 8

Species Level Identification of Yeast and Yeast Like Fungus for Prompt Infection Control Measures in Prevention of Outbreaks: With Special Reference to Candida auris in Pre-covid Era

Gitali Bhagawati1,2*, Sarita Rani Jaiswal2,3, Ashutosh Bhardwaj2,4, Navneet Sood2,5, Rekha Saji Kumar1, Lincy TP2, Sania Paul1, Mansi1and Suparno Chakrabarti2,3

1Department of Microbiology, Dharamshila Narayana Superspeciality Hospital and Research Centre, New Delhi, India
2Hospital Infection Control Team, Dharamshila Narayana Superspeciality Hospital and Research Centre, New Delhi, India
3Department of Blood and Marrow Transplantation, Dharamshila Narayana Superspeciality Hospital and Research Centre, New Delhi, India
4Critical Care Medicine, Dharamshila Narayana Superspeciality Hospital and Research Centre, New Delhi, India
5Department of Pulmonology, Narayana Superspeciality Hospital and Research Centre, New Delhi, India

*Corresponding Author: Gitali Bhagawati, Consultant and Head, Department of Microbiology and Infection Control, Dharmshila Narayana Superspeciality Hospital, Vasundhara Enclave, Delhi, India.

Received: June 03, 2021 ; Published: July 09, 2021

Abstract

Background: Candida auris (C. auris) is emerging as a multi-drug resistant (MDR) strain of Candida amongst Non-albicans Candida (NAC) which poses a serious risk of nosocomial spread with high mortality rate.

Aim: Aim of the study is to give emphasis on species level identification of all yeast and yeast like fungus (YYLF) for the implementation of infection control practices (ICP) to prevent outbreak, with special reference to C. auris.

Methods: The study was done over a period of 12 months in a tertiary care hospital. YYLF isolated from primary culture were further sub-cultured on Sabouroud Dextrose Agar (SDA) and incubated at 25°C and 37°C for 72 hours. Identification and antifungal susceptibility was done using Vitek 2 Compact system 8.01 (bioMérieux, North Carolina/USA). The 1st two isolates were confirmed by molecular method (D1-D2 sequencing). C. auris specific containment measures were implemented in the early part of the study. Clinical data and outcome were evaluated at end of the period.

Findings: Out of 2,487 non-duplicate samples processed over 12 months, YYLF were isolated from 209 (8.40%) samples. Amongst the YYLF, predominant isolate was C. albicans (109/209, 52.15%), followed by C. tropicalis (35/209, 16.74%). Predominant source was urinary samples (115/209, 55%) followed by respiratory samples (60/209, 28%). C. auris was isolated in 7 non-duplicate samples (7/209, 3.35%). Out of these 7 cases, 5 had history of cancer (72.42%). Measures for containment of C. auris were placed prior to the study and implemented at each time of its isolation. No nosocomial spread was detected during this study period.

Conclusion and Clinical Significance: Species level identification following proper quality control in microbiology laboratory along with appropriate sample collection can act as a primer in controlling outbreaks by YYLF. Pre-emptive implementation of hospital infection control (HIC) policies can help in controlling the MDR C.auris, even amongst immunocompromised patients.

Keywords: c. auris; Multi Drug Resistant; Non-albicans Candida; Infection Control Practices; Yeast and Yeast-like Fungus; Hospital Infection Control

References

  1. Satoh K., et al. “Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital”. Microbiology Immunology 53 (2009): 41-44.
  2. Kim MN., et al. “Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features”. Clinical Infectious Diseases 48 (2009): 57-61.
  3. Chowdhary A., et al. “New clonal strain of Candida auris, Delhi, India”. Emergency Infectious Diseases 19 (2013): 1670-1673.
  4. Dal Mas C., et al. “Effects of the Natural Peptide Crotamine from a South American Rattlesnake on Candida auris, an Emergent Multidrug Antifungal Resistant Human Pathogen”. Biomolecules6 (2019): 205.
  5. Lockhart SR., et al. “Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses”. Clinical Infectious Diseases 64 (2017): 134-140.
  6. Casadevall A., et al. “On the Emergence of Candida auris: Climate Change, Azoles, Swamps, and Birds”. American Society for Microbiology4 (2019): 01397-1419.
  7. LJR Milne. Fungi. Mackie and McCartney Practical Medical Microbiology. J.G. Colle, A.G. Fraser, B.P. Marmion, A. Simmons Elsevier 14 (2008): 695-717
  8. “Bailey and Scott’s Diagnostic Microbiology”. Betty A. Eorbes, Daniel F.Sahm, Alice S. Weissfeld. Infections of Urinary tract. Mosby Elsevier 12 (2007): 842-855
  9. Wong LK., et al. “Comparison of six different criteria for judging the acceptability of sputum specimens”. Journal of Clinical Microbiology 4 (1982): 627-631.
  10. JG Collee and W Marr. “Culture of Bacteria”. Mackie and McCartney Practical medical Microbiology. Elsevier 14 (2008): 113-129.
  11. https:/www.cdc.gov>fungal>candida auris> Identification of Candida auris.
  12. https:/www.cdc.gov>fungal>candida auris>antifungal susceptibility pattern and interpretation.
  13. https:/www.icmr.nic.in>sites>default>files>guidelines>candida auris.
  14. https://www.cdc.gov>fungal>candida auris>laboratories and Health Professionals> Infection Prevention and Control.
  15. Pfaller MA and Diekema DJ. “Epidemiology of invasive candidiasis: a persistent public health problem”. Clinical Microbiology Review1 (2007): 133-163.
  16. Tritipwanit K., et al. “Epidemiology of candidemia at King Chulalongkorn Memorial Hospital, Thailand”. Journal of Infectious Diseases and Antimicrobial Agents 22 (2005): 59-69.
  17. Fu J., et al. “Epidemiology of Candida albicans and non-C.albicans of neonatal candidemia at a tertiary care hospital in western China”. BMC Infectious Diseases1 (2017): 329.
  18. Cortegiani A., et al. “Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris”. Journal of Intensive Care6 (2018): 69.
  19. Chakrabarti A., et al. “Incidence, characteristics and outcome of ICU-acquired candidemia in India”. Intensive Care Medicine2 (2015): 285-295.
  20. Sayeed MA., et al. “Clinical spectrum and factors impacting outcome of Candida auris: a single center study from Pakistan”. BMC Infectious Diseases 19 (2019): 384.

Citation

Citation: Gitali Bhagawati., et al. “Species Level Identification of Yeast and Yeast Like Fungus for Prompt Infection Control Measures in Prevention of Outbreaks: With Special Reference to Candida auris in Pre-covid Era ”. Acta Scientific Microbiology 4.8 (2021): 19-25.

Copyright

Copyright: © 2021 Gitali Bhagawati., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor0.810

Indexed In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is October 20, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US